217 related articles for article (PubMed ID: 34396603)
1. Large-Sized Graphene Oxide Nanosheets Increase DC-T-Cell Synaptic Contact and the Efficacy of DC Vaccines against SARS-CoV-2.
Zhou Q; Gu H; Sun S; Zhang Y; Hou Y; Li C; Zhao Y; Ma P; Lv L; Aji S; Sun S; Wang X; Zhan L
Adv Mater; 2021 Oct; 33(40):e2102528. PubMed ID: 34396603
[TBL] [Abstract][Full Text] [Related]
2. Alum-functionalized graphene oxide nanocomplexes for effective anticancer vaccination.
Wang X; Cao F; Yan M; Liu Y; Zhu X; Sun H; Ma G
Acta Biomater; 2019 Jan; 83():390-399. PubMed ID: 30448435
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous Protein Adsorption on Graphene Oxide Nanosheets Allowing Efficient Intracellular Vaccine Protein Delivery.
Li H; Fierens K; Zhang Z; Vanparijs N; Schuijs MJ; Van Steendam K; Feiner Gracia N; De Rycke R; De Beer T; De Beuckelaer A; De Koker S; Deforce D; Albertazzi L; Grooten J; Lambrecht BN; De Geest BG
ACS Appl Mater Interfaces; 2016 Jan; 8(2):1147-55. PubMed ID: 26694764
[TBL] [Abstract][Full Text] [Related]
4. Laponite Lights Calcium Flickers by Reprogramming Lysosomes to Steer DC Migration for An Effective Antiviral CD8
Li C; Hou Y; He M; Lv L; Zhang Y; Sun S; Zhao Y; Liu X; Ma P; Wang X; Zhou Q; Zhan L
Adv Sci (Weinh); 2023 Oct; 10(30):e2303006. PubMed ID: 37638719
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
6. Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response.
Roßmann L; Bagola K; Stephen T; Gerards AL; Walber B; Ullrich A; Schülke S; Kamp C; Spreitzer I; Hasan M; David-Watine B; Shorte SL; Bastian M; van Zandbergen G
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34561306
[TBL] [Abstract][Full Text] [Related]
7. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
8. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination immunology in SARS-CoV-2].
Helweg-Larsen J; Benfield T
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccines: modes of immune activation and future challenges.
Teijaro JR; Farber DL
Nat Rev Immunol; 2021 Apr; 21(4):195-197. PubMed ID: 33674759
[TBL] [Abstract][Full Text] [Related]
11. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
[TBL] [Abstract][Full Text] [Related]
12. IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant.
Bekele Y; Sui Y; Berzofsky JA
Front Immunol; 2021; 12():737406. PubMed ID: 34603318
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
15. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
16. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
17. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
Front Immunol; 2021; 12():748103. PubMed ID: 34867974
[TBL] [Abstract][Full Text] [Related]
18. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
Front Immunol; 2021; 12():729189. PubMed ID: 34603303
[TBL] [Abstract][Full Text] [Related]
19. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
20. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
Zhang N; Li K; Liu Z; Nandakumar KS; Jiang S
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
